Prognostic Impact of Claudin18.2 and TROP2 Expression in Advanced Gastric Cancer Treated With Nivolumab
{{output}}
Background/aim: The combination of chemotherapy and nivolumab has become the standard first-line therapy for advanced gastric cancer (AGC) following the results of the CheckMate 649 and ATTRACTION-4 trials. Claudin18.2 (CLDN18.2)... ...
